Inicio › Linfoma no Hodgkin › Washington › Seattle
Ensayos clínicos de Linfoma no Hodgkin en Seattle, WA
16 estudios para Linfoma no Hodgkin buscan participantes en centros de Seattle y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ReclutandoFase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
ReclutandoFase 1
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ReclutandoFase 1
- Swedish Cancer Institute (SCI), Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutandoFase 2
- Swedish Cancer Institute, Seattle
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
ReclutandoFase 1/2
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
ReclutandoFase 1
- Fred Hutch Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
DALY II USA/ MB-CART2019.1 for DLBCL
ReclutandoFase 2
- Fred Hutchinson Cancer Center, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- Fred Hutchinson Cancer Research Center, Seattle
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
ReclutandoFase 1/2
- University of Washington Medical Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
ReclutandoEstudio observacional
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
ReclutandoFase 4
- Swedish Cancer Institute, Seattle
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
ReclutandoFase 4
- Swedish Cancer Institute, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
ReclutandoFase 1
- Swedish Cancer Institute, Seattle
Ensayos de Linfoma no Hodgkin en otras ciudades
- Houston, TX31 estudios
- New York City, NY31 estudios
- Boston, MA26 estudios
- Nashville, TN21 estudios
- Philadelphia, PA20 estudios
- Baldwin Park, CA19 estudios
- Atlanta, GA18 estudios
- Columbus, OH18 estudios
- Chicago, IL18 estudios
- Milwaukee, WI18 estudios
- Washington, DC18 estudios
- Dallas, TX17 estudios
Otros estudios en Seattle
- Cáncer de pulmón de células no pequeñas53 estudios
- Cáncer (todos los tipos)49 estudios
- Cáncer de próstata42 estudios
- Leucemia mielógena aguda40 estudios
- Cáncer de seno39 estudios
- Cáncer metastásico39 estudios
- Cáncer del colon y del recto34 estudios
- Cáncer de pulmón33 estudios
- Cáncer de ovario30 estudios
- Mieloma múltiple22 estudios
- Síndromes mielodisplásicos21 estudios
- Leucemia linfoblástica aguda21 estudios
De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.